Arrowhead spotlights key pancreatitis figures from Phase 3 lipid disease study to differentiate itself from Ionis

Arrowhead Pharmaceuticals has unveiled highly anticipated pancreatitis results from a late-phase trial of plozasiran for a rare lipid disorder, several months after reporting topline data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

First gene therapies for sickle cell disease secure FDA approval – Pharmaceutical Technology

Share this article More than 100,000 people live with sickle cell disease in the US, with the most patients being African American. Image credit: Shutterstock/Ezume

December 11, 2023

Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin | Psychedelic Invest

Psyence Biomedical Ltd. issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic

March 20, 2024

Noom Co-Founder Artem Petakov Transitions to Head Noom Ventures

Noom Co-Founder Artem Petakov What You Should Know: – Noom, a digital healthcare company focused on chronic disease prevention and healthy living, today announced that

March 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.